About InCephalo
InCephalo is a company based in Allschwil (Switzerland) founded in 2021 by Carlo Bertozzi. InCephalo offers products and services including In C01 and C-Lock Technology. InCephalo operates in a competitive market with competitors including Imvax, GT Medical Technologies, Basilea, Laminar Pharma and SOM Biotech, among others.
- Headquarter Allschwil, Switzerland
- Founders Carlo Bertozzi
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InCephalo
InCephalo offers a comprehensive portfolio of products and services, including In C01 and C-Lock Technology.
Treats brain cancers by enhancing local immune response with reduced toxicity.
Enables localized biologics retention in CNS to minimize systemic side effects.
Funding Insights of InCephalo
Detailed funding history for InCephalo
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InCephalo
Investment portfolio details for InCephalo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InCephalo
Detailed financials for InCephalo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Incephalo Comparisons
Peer comparison for InCephalo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InCephalo
InCephalo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Imvax, GT Medical Technologies, Basilea, Laminar Pharma and SOM Biotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Patient-specific cell vaccines for glioma treatment are developed.
|
|
| Locked | Locked | Locked |
Medical devices for brain tumor radiation therapy are provided.
|
|
| Locked | Locked | Locked |
Antibiotics, antifungals, and oncology drugs are developed for disease treatment.
|
|
| Locked | Locked | Locked |
Melipathy-based drugs are developed for cancer, Alzheimer's, and inflammation treatments.
|
|
| Locked | Locked | Locked |
Developer of platform for screening compounds to treat rare diseases
|
|
| Locked | Locked | Locked |
Therapeutic drugs for cancer, eye, and infectious diseases are developed.
|
Detailed competitors of InCephalo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Incephalo
Complete news archive for InCephalo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InCephalo
InCephalo was founded in 2021.
InCephalo is headquartered in Allschwil, Switzerland. It is registered at Allschwil, Basel-landschaft, Switzerland.
Carlo Bertozzi is the current CEO of InCephalo. They have also founded this company.
InCephalo was founded in 2021 in Allschwil, Switzerland, within the biotechnology sector. Therapeutics targeting neurological disorders are developed, with a focus on proprietary Compartment Lock technology that retains locally applied biologics behind the blood-brain barrier. Operations center on advancing drug candidates for brain-related conditions. The lead product, IL-12, functions as a proinflammatory cytokine to regulate anti-tumor immune responses in brain cancer treatments.
InCephalo's top competitors include Imvax, GT Medical Technologies and Basilea.
InCephalo offers In C01 and C-Lock Technology.